Last reviewed · How we verify
Low dose carbamazepine
Low-dose carbamazepine reduces sodium channel activity and stabilizes neuronal membranes to prevent abnormal electrical activity.
Low-dose carbamazepine blocks sodium channels in neuronal membranes, reducing repetitive neuronal firing and stabilizing the threshold for action potential generation. Used for Epilepsy, Trigeminal neuralgia, Bipolar disorder.
At a glance
| Generic name | Low dose carbamazepine |
|---|---|
| Also known as | low carbamazepine |
| Sponsor | Mario Negri Institute for Pharmacological Research |
| Drug class | Anticonvulsant / Antiepileptic drug |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Carbamazepine is an anticonvulsant that blocks voltage-gated sodium channels, reducing the repetitive firing of action potentials in neurons. At low doses, it may also modulate calcium channels and enhance GABAergic neurotransmission. This stabilization of neuronal membranes prevents seizure propagation and abnormal electrical discharges.
Approved indications
- Epilepsy / seizure disorders
- Trigeminal neuralgia
- Bipolar disorder (off-label or approved depending on region)
Common side effects
- Dizziness
- Ataxia / coordination problems
- Diplopia / blurred vision
- Nausea
- Hyponatremia
- Rash / Stevens-Johnson syndrome
- Agranulocytosis
Key clinical trials
- A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female Participants (PHASE1)
- Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW) (PHASE4)
- Drug-Drug Interaction Study Assessing Effect of Carbamazepine on PF-07321332 Boosted With Ritonavir (PHASE1)
- The Efficacy and Safety of Low Dose Combination of LTG and VPA Compared to CBZ Monotherapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low dose carbamazepine CI brief — competitive landscape report
- Low dose carbamazepine updates RSS · CI watch RSS
- Mario Negri Institute for Pharmacological Research portfolio CI